Barriers to Insulin Initiation

The Translating Research Into Action for Diabetes Insulin Starts Project

Andrew J. Karter, PhD1,2
Usha Subramanian, MD, MS3
Chandan Saha, PhD4
Jesse C. Crosson, PhD5

Melissa M. Parker, MS1
Bix E. Swain, MS1
Howard H. Moffet, MPH1
David G. Marrero, PhD6

OBJECTIVE — Reasons for failing to initiate prescribed insulin (primary nonadherence) are poorly understood. We investigated barriers to insulin initiation following a new prescription.

RESEARCH DESIGN AND METHODS — We surveyed insulin-naïve patients with poorly controlled type 2 diabetes, already treated with two or more oral agents who were recently prescribed insulin. We compared responses for respondents prescribed, but never initiating, insulin (n = 69) with those dispensed insulin (n = 100).

RESULTS — Subjects failing to initiate prescribed insulin commonly reported misconceptions regarding insulin risk (35% believed that insulin causes blindness, renal failure, amputations, heart attacks, strokes, or early death), plans to instead work harder on behavioral goals, a sense of personal failure, low self-efficacy, injection phobia, hypoglycemia concerns, negative impact on social life and job, inadequate health literacy, health care provider inadequately explaining risks/benefits, and limited insulin self-management training.

CONCLUSIONS — Primary adherence for insulin may be improved through better provider communication regarding risks, shared decision making, and insulin self-management training.

Diabetes Care 33:733–735, 2010

Insulin is typically recommended for patients with type 2 diabetes if they have failed to achieve adequate glycemic control despite treatment with multiple oral agents at maximal dose (1), especially when β-cell function declines (2, 3). Despite the known benefits of insulin, many patients fail to begin insulin treatment (4). In a previous study (5), we followed a cohort of patients with diabetes who were prescribed new glucose-lowering medications. We observed that 4.5% of insulin-naïve patients who were prescribed insulin never filled that prescription (were primary nonadherent) and an additional 25.5% had zero refills (early-stage nonpersistence). Thus, one in three insulin-naïve patients who were prescribed insulin never became ongoing users.

A patient’s reluctance to initiate insulin has been dubbed psychological insulin resistance (PIR) (6). Current understanding of PIR is based largely on surveys of insulin-naïve patients queried about their hypothetical willingness to initiate insulin (7, 8). However, the reasons why patients fail to initiate therapy after actually agreeing to and receiving a first prescription for insulin have not been explored. In this study, we evaluate barriers and attitudes among insulin-naïve patients who had failed to initiate newly prescribed insulin therapy (i.e., primary nonadherent) versus those who did initiate insulin therapy (i.e., primary adherent).

RESEARCH DESIGN AND METHODS — Subjects for this study of insulin adherence came from Kaiser Permanente Northern California (Kaiser) and Horizon Blue Cross Blue Shield of New Jersey and were participants in the Translating Research Into Action for Diabetes (TRIAD) Study (7), an ongoing study of quality of care and self-care for people with diabetes in managed-care settings across the U.S.

We identified poorly controlled, insulin-naïve and insulin-eligible type 2 diabetic patients receiving a new electronic prescription for insulin. Eligibility criteria included: 1) newly prescribed insulin during August 2007 to February 2008, 2) Two or more diagnoses for type 2 diabetes 18 months prior to the new insulin prescription, 3) no insulin use in prior 2 years, 4) already taking one oral agent at maximum and a second oral agent at maximal/submaximal dose, 5) two consecutive A1Cs ≥8% 2.5–12 months apart or last A1C ≥9%, and 6) two or more clinic visits in the previous 12 months. Patients aged >85 years, with limited English proficiency, life-limiting malignancy, hospice care enrollment, significant cognitive deficits, psychiatric illness (excluding major depression), or visual impairment limiting insulin self-administration, were excluded.

We identified a random sample of eligible subjects who were primary adherent (at least one dispensing of insulin) and primary nonadherent (not dispensed the newly prescribed insulin within 60 days of the prescribing date) from pharmacy records. Computer-assisted telephone interviews and self-administered mailed surveys were used to collect insulin treatment, provider communication, self-management training, health literacy (8), and depressive symptoms (9). We used standard American Association for Public

From the 1Division of Research, Kaiser Permanente, Oakland, California; the 2School of Public Health & Community Health, University of Washington, Seattle, Washington; the 3Roudebush VA Medical Center and Division of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; the 4Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana; the 5Research Division, Department of Family Medicine and Community Health, the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, Somerset, New Jersey; and the 6Diabetes Translational Research Center, Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, Indiana.

Corresponding author: Andrew J. Karter, andy.j.karter@kp.org
Received 20 June 2009 and accepted 6 January 2009. Published ahead of print at http://care.diabetesjournals.org on 19 January 2010. DOI: 10.2337/dc09-1184.

The contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the National Institute of Diabetes and Digestive and Kidney Diseases. © 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Opinion Research (AAPOR) algorithms for calculating response rates (10). The human subjects review boards in the TRIAD translational research centers involved with this study (Kaiser, the University of Medicine and Dentistry of New Jersey, and Indiana University) approved this study.

RESULTS — We mailed an invitation letter to 195 and 186 primary nonadherent and adherent subjects, respectively, following approval of their providers. Sixty-nine nonadherent and 100 adherent patients responded to the survey and are the basis for this study. The AAPOR response rate, which assumes that those who could not be contacted for eligibility confirmation had the same proportion of eligibility as those contacted, was 60% overall (50% in the nonadherent and 68% in adherent group). The cooperation rate (percent survey completion among eligible subjects we were able to reach) was 98% (100% in the nonadherent and 92% in adherent group). None of the patient characteristics differed significantly between adherent and nonadherent subjects. Nonadherent subjects had a mean age of 61 years and 35% were women, 49% were of a minority ethnic heritage, 37% had an income <$40,000, 33% had no college education, and 48% were retired or unemployed. Adherent subjects had a mean age of 58 years and 47% were women, 54% were of minority ethnic heritage, 22% had an income <$40,000, 31% had no college education, and 33% were retired or unemployed.

Among nonadherent patients, the most commonly cited reasons for failing to initiate insulin included the following reasons: The patient planned to change health behaviors instead of starting insulin (25%), injection phobia (13%), negative impact on work (9%), concerns about long-term medication use (9%), inconvenience (6%), and not believing insulin was needed (6%). Nonadherent patients believed “people who require insulin have not taken care of themselves in the past” (47%) and that “taking insulin can cause…blindness (20%), renal failure (32%), amputations (15%), heart attacks or strokes (19%), and early death (19%). In all, 35% of the insulin-nonadherent group reported that they believed insulin causes harm (at least one of the possible complications listed above).

Compared with adherent patients, nonadherent patients expressed significantly more concern about their inability to adjust insulin dosage, the impact on social life and work, injection pain, and side effects, particularly hypoglycemia (Table 1). Significantly more nonadherent patients reported problems learning about their medical condition because of difficulty understanding written information (inadequate health literacy) and claimed providers failed to adequately explain insulin's risk and benefits. Substantially fewer nonadherent patients reported receiving insulin self-management training from their doctor, nurse, health educator, or a class.

CONCLUSIONS — Among poorly controlled patients with type 2 diabetes newly prescribed insulin, the major predictors of insulin nonadherence included plans to improve health behaviors in lieu of starting insulin, negative impact on social and work life, injection phobia, and concerns about side effects or hypoglycemia. Nonadherent patients often blamed themselves, believing prior poor self-management caused the current need for insulin and erroneously conceptualized insulin as itself the cause of future complications. These patient-level findings are consistent with previous studies of attitudes about insulin (11,12).

Not previously reported is our finding that nonadherent patients frequently felt their provider had not adequately explained the risks and benefits of insulin. The importance of provider communication is underscored by the association between insulin initiation and health literacy (13). Primary nonadherence
likely also reflects inadequate shared decision making or lack of self-management training. Interventions for PIR need to address both provider- and system-level factors (14–16).

Acknowledgments — This research was funded jointly through TRIAD (program announcement no. 04005 from the Division of Diabetes Translation, Centers for Disease Control and Prevention, and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [R01 DK066564 and R01 DK080726, RC1 DK086178]).

No potential conflicts of interest relevant to this article were reported.

The authors acknowledge the participation of the two health plan partners (Kaiser Permanente Northern California and Horizon Blue Cross Blue Shield of New Jersey) and the TRIAD staff and participants who made this study possible.

References


